Rick Greupink

List of Publications by Year
in descending order

54 papers	1,352 citations	293460 24 h-index	406436 35 g-index
56 all docs	56 docs citations	56 times ranked	2051 citing authors

#	Article	IF	Citations
1	Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. Journal of Clinical Pharmacology, 2022, 62, 385-396.	1.0	4
2	Effects of tumor necrosis factor on undifferentiated and syncytialised placental choriocarcinoma BeWo cells. Toxicology in Vitro, 2022, 80, 105327.	1.1	0
3	ExÂvivo dual perfusion of an isolated human placenta cotyledon: Towards protocol standardization and improved inter-centre comparability. Placenta, 2022, 126, 83-89.	0.7	7
4	Nonâ€clinical considerations for supporting accelerated inclusion of pregnant women in preâ€licensure clinical trials with antiâ€HIV agents. Journal of the International AIDS Society, 2022, 25, .	1.2	4
5	Placental disposition of eculizumab, C5 and C5â€eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria. British Journal of Clinical Pharmacology, 2021, 87, 2128-2131.	1.1	6
6	Toxicity of anticancer drugs in human placental tissue explants and trophoblast cell lines. Archives of Toxicology, 2021, 95, 557-571.	1.9	19
7	Transfer of uremic solutes across the human term placenta: An ex vivo study in the dual-side perfused cotyledon. Placenta, 2021, 104, 220-231.	0.7	3
8	Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologicallyâ€Based Pharmacokinetic Modeling. Clinical Pharmacology and Therapeutics, 2020, 107, 1352-1361.	2.3	30
9	Transfer of daclatasvir and sofosbuvirâ€™s main metabolite, GS-331007, across the human placenta exÂvivo. American Journal of Obstetrics and Gynecology, 2020, 223, 941-943.	0.7	3
10	Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta. Clinical Pharmacology and Therapeutics, 2020, 108, 99-106.	2.3	18
11	Impact of gastrointestinal physiology on drug absorption in special populationsâ€“â€“An UNGAP review. European Journal of Pharmaceutical Sciences, 2020, 147, 105280.	1.9	142
12	A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2020, 31, 650-662.	3.0	35
13	Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. Clinical Pharmacokinetics, 2019, 58, 309-323.	1.6	41
14	Review article: directâ€acting antivirals for the treatment of HCV during pregnancy and lactation â€• implications for maternal dosing, foetal exposure, and safety for mother and child. Alimentary Pharmacology and Therapeutics, 2019, 50, 738-750.	1.9	35
15	Differential effects of psychoactive substances on human wildtype and polymorphic T356M dopamine transporters (DAT). Toxicology, 2019, 422, 69-75.	2.0	10
16	Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy, 2019, 74, 1348-1356.	1.3	8
17	Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity. Toxicology in Vitro, 2019, 56, 52-61.	1.1	22
18	Placental disposition of the immunosuppressive drug tacrolimus in renal transplant recipients and in ex vivo perfused placental tissue. European Journal of Pharmaceutical Sciences, 2018, 119, 244-248.	1.9	20

#	Article	IF	Citations
19	Microbial Glucuronidase Inhibition Reduces Severity of Diclofenac-Induced Anastomotic Leak in Rats. Surgical Infections, 2018, 19, 417-423.	0.7	18
20	Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 103-110.	1.3	51
21	Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs. European Journal of Pharmaceutical Sciences, 2018, 115, 175-184.	1.9	12
22	A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400Âmg in Pregnant Women. Clinical Pharmacokinetics, 2018, 57, 1421-1433.	1.6	6
23	Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics, 2018, 57, 705-716.	1.6	43
24	Experimental study of diclofenac and its biliary metabolites on anastomotic healing. BJS Open, 2018, 2, 220-228.	0.7	1
25	Rat precision-cut liver slices predict drug-induced cholestatic injury. Archives of Toxicology, 2017, 91, 3403-3413.	1.9	14
26	Editorâ€™s Highlight: Placental Disposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicological Sciences, 2017, 157, 500-509.	1.4	19
27	Free dug concentrations in pregnancy: Bound to measure unbound?. British Journal of Clinical Pharmacology, 2017, 83, 2595-2598.	1.1	22
28	Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease. Scientific Reports, 2017, 7, 11733.	1.6	33
29	First reported use of elvitegravir and cobicistat during pregnancy. Aids, 2016, 30, 807-808.	1.0	20
30	Development of a mechanistic biokinetic model describing hepatic bile acid handling to predict possible cholestatic effects of drugs. Toxicology Letters, 2016, 258, S47.	0.4	0
31	Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman. Aids, 2016, 30, 1999-2001.	1.0	10
32	Placental transfer of the HIV integrase inhibitor dolutegravir in anex vivohuman cotyledon perfusion model. Journal of Antimicrobial Chemotherapy, 2016, 71, 480-483.	1.3	34
33	Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy. Clinical Pharmacokinetics, 2016, 55, 381-396.	1.6	40
34	Convallatoxin: A new P-glycoprotein substrate. European Journal of Pharmacology, 2014, 744, 18-27.	1.7	12
35	In Silico Identification and in Vitro Validation of Potential Cholestatic Compounds through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors. Chemical Research in Toxicology, 2014, 27, 873-881.	1.7	28
36	Interaction of Digitalis-Like Compounds with Liver Uptake Transporters NTCP, OATP1B1, and OATP1B3. Molecular Pharmaceutics, 2014, 11, 1844-1855.	2.3	32

#	Article	IF	Citations
37	Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drugâ€“drug-interactions. European Journal of Pharmaceutical Sciences, 2013, 49, 819-828.	1.9	19
38	Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 andÂMRP4. Translational Research, 2013, 162, 398-409.	2.2	61
39	Drug-Drug Interactions between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1. Drug Metabolism and Disposition, 2013, 41, 592-601.	1.7	56
40	Pharmacological considerations on the use of antiretrovirals in pregnancy. Current Opinion in Infectious Diseases, 2013, 26, 575-588.	1.3	29
41	Interaction of Digitalis-Like Compounds with P-Glycoprotein. Toxicological Sciences, 2013, 131, 502-511.	1.4	27
42	In Silico Identification of Potential Cholestasis-Inducing Agents via Modeling of Na+-Dependent Taurocholate Cotransporting Polypeptide Substrate Specificity. Toxicological Sciences, 2012, 129, 35-48.	1.4	29
43	Exploiting Transport Activity of P-Glycoprotein at the Bloodâ€“Brain Barrier for the Development of Peripheral Cannabinoid Type 1 Receptor Antagonists. Molecular Pharmaceutics, 2012, 9, 1351-1360.	2.3	17
44	Interaction of fluvastatin with the liver-specific Na+-dependent taurocholate cotransporting polypeptide (NTCP). European Journal of Pharmaceutical Sciences, 2011, 44, 487-496.	1.9	40
45	Targeting fibrosis with selective drug carriers. Arab Journal of Gastroenterology, 2010, 10, S27-S29.	0.4	0
46	Reprint of: Targeting fibrosis with selective drug carriers. Arab Journal of Gastroenterology, 2010, 11, 63-65.	0.4	0
47	Evaluation of a 99mTc-Labeled AnnexinA5 Variant for Non-invasive SPECT Imaging of Cell Death in Liver, Spleen and Prostate. Pharmaceutical Research, 2009, 26, 2647-2656.	1.7	13
48	Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats. Biochemical Pharmacology, 2007, 73, 1455-1462.	2.0	9
49	Targeting 15d-Prostaglandin J2 to Hepatic Stellate Cells: Two Options Evaluated. Pharmaceutical Research, 2007, 24, 566-574.	1.7	42
50	Mannose-6-Phosphate/Insulin-Like Growth Factor-II Receptors may Represent a Target for the Selective Delivery of Mycophenolic Acid to Fibrogenic Cells. Pharmaceutical Research, 2006, 23, 1827-1834.	1.7	33
51	Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. Journal of Controlled Release, 2006, 111, 193-203.	4.8	50
52	The Antiproliferative Drug Doxorubicin Inhibits Liver Fibrosis in Bile Duct-Ligated Rats and Can Be Selectively Delivered to Hepatic Stellate Cells in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 514-521.	1.3	53
53	Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. Journal of Hepatology, 2005, 43, 884-892.	1.8	40
54	POTENTIALS AND LIMITATIONS OF THE LOW-MOLECULAR-WEIGHT PROTEIN LYSOZYME AS A CARRIER FOR RENAL DRUG TARGETING. Renal Failure, 2001, 23, 397-409.	0.8	29